OptiBiotix Health PLC Proposed directorate changes (3267Y)
December 05 2017 - 2:01AM
UK Regulatory
TIDMOPTI
RNS Number : 3267Y
OptiBiotix Health PLC
05 December 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Proposed directorate changes
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that subject to the completion of normal
regulatory due diligence Neil Davidson CBE will be appointed as
Non- Executive Chairman on 1 January 2018.
Adam Reynolds, the current Non-Executive Chairman will step down
on 31 December 2017.
Neil brings to the Board over thirty years of operational and
Board experience as Chairman and Chief Executive of FTSE 100, AIM,
and private companies in both an executive and non-executive
capacity.
Neil has a wealth of commercial expertise in the food and retail
sectors having started his career with Northern Foods plc, where he
rose to become Managing Director of its milk division. He
subsequently became Chief Executive of Express Dairies plc and then
Arla Foods plc before taking on a number of Board positions in FTSE
listed and private companies.
Neil's experience in the public markets includes non-executive
positions with a number of FTSE 100 companies such as Persimmons
plc (GBP3.1bn revenue: 2016) from 2004-2013 and Wm Morrison
Supermarkets (16.3bn revenue: 2016), where he is currently a
Non-Executive Director. Neil was also Non-Executive Chairman of AIM
quoted Produce Investments plc. Neil was awarded a CBE for services
to the food and dairy industry in 2006.
Neil has a personal interest in the development and
commercialisation of technology to improve health. He was Chairman
of Eminate, a spin out from the University of Nottingham which
developed an alternative to salt which was licensed to Tate and
Lyle, and Cherry Valley Farms, a genetics business which had
extensive operations in China and the Far East, which was sold to
an Asian private equity group in 2010. Neil has an extensive
network of industry contacts and experience in sector specific
M&A transactions.
Stephen O'Hara, CEO of OptiBiotix, commented: "I am delighted to
welcome Neil to the Board. He brings a unique mix of sector
specific commercial expertise and a track record of building
shareholder value. His network of contacts and wealth of experience
on the Board of some of the UK's largest public companies will help
guide OptiBiotix as it builds a microbiome business in what is
forecast to be one of the world's fastest growth areas. The Board
anticipates a future where microbiome products will be at the
forefront of preventing, managing and treating many of today's
chronic lifestyle disease and we hope under Neil's guidance
OptiBiotix will continue to be one of the world's leaders in this
exciting and emerging field.
On behalf of the Board, I would like to thank Adam Reynolds, our
outgoing interim Chairman, for his substantive contribution in
helping guide OptiBiotix through its early developmental years.
Adam has been an integral part of OptiBiotix's success and we wish
him well in his future projects."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP Tel: 020 7213
0883
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAZZLFBDLFEFBE
(END) Dow Jones Newswires
December 05, 2017 02:01 ET (07:01 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024